n-methyl-3,4-methylenedioxyamphetamine has been researched along with Atherosclerotic Parkinsonism in 13 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beaudoin-Gobert, M | 1 |
| Météreau, E | 1 |
| Duperrier, S | 1 |
| Thobois, S | 1 |
| Tremblay, L | 1 |
| Sgambato, V | 1 |
| Lappin, JM | 1 |
| Sara, GE | 1 |
| Schmidt, WJ | 1 |
| Mayerhofer, A | 1 |
| Meyer, A | 1 |
| Kovar, KA | 1 |
| Parrott, AC | 2 |
| Buchanan, T | 2 |
| Heffernan, TM | 1 |
| Scholey, A | 1 |
| Ling, J | 2 |
| Rodgers, J | 2 |
| Kuniyoshi, SM | 1 |
| Jankovic, J | 1 |
| Sumnall, HR | 1 |
| Jerome, L | 2 |
| Doblin, R | 2 |
| Mithoefer, MC | 1 |
| Scholey, AB | 1 |
| Heffernan, T | 1 |
| Kish, SJ | 1 |
| Mithoefer, M | 1 |
| Mintzer, S | 1 |
| Hickenbottom, S | 1 |
| Gilman, S | 1 |
| Borg, GJ | 1 |
| Sewell, RA | 1 |
| Cozzi, NV | 1 |
| Baggott, M | 1 |
| Mendelson, J | 1 |
| Jones, R | 1 |
2 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Psychostimulant use and the brain.
Topics: Amphetamine; Amphetamine-Related Disorders; Brain; Central Nervous System Stimulants; Cocaine; Cocai | 2019 |
What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
Topics: Brain; Carrier Proteins; Hallucinogens; Humans; Membrane Glycoproteins; Membrane Transport Proteins; | 2003 |
11 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates.
Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug- | 2018 |
Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Animals; Catalepsy; Dopamine Antagonist | 2002 |
Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.
Topics: Brain; Dopamine; Hallucinogens; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Parki | 2003 |
MDMA and Parkinsonism.
Topics: Adult; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secondary | 2003 |
Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.
Topics: Animals; Dopamine; Hallucinogens; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Neu | 2004 |
The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).
Topics: Animals; Clinical Trials as Topic; Dopamine; Hallucinogens; Humans; Illicit Drugs; N-Methyl-3,4-meth | 2004 |
Ecstasy use-Parkinson's disease link tenuous.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Dose-Response Relationship, Drug; Hallucinogens; | 2004 |
Parkinsonism after taking ecstasy.
Topics: Adult; Hallucinogens; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secon | 1999 |
More about parkinsonism after taking ecstasy.
Topics: Adult; Deception; Ethics, Medical; Hallucinogens; Humans; Male; Marijuana Abuse; N-Methyl-3,4-methyl | 1999 |
More about parkinsonism after taking ecstasy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Basal Ganglia; Dopamine Agents; Hallucinogens; Humans; | 1999 |
More about parkinsonism after taking ecstasy.
Topics: Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secondary; Time Fa | 1999 |